MabPlex International, LTD. has a construction area of 40000m2 and a land area of 28 acres. After phaseⅡproject completed by 2018, the new antibody production lines will have 12 2000L single-use bioreactors and corresponding purification and filling equipment. The ADC production line will have the largest facility (150L conjugation volume) in Asia. These can meet our customers’ need for Phase Ⅲ clinical studies and commercial production. Mabplex provides one-step and high-quality CRO/CMO solutions for biologics to our global clients from R&D to production and drug registration. Supported by our large-scale protein expression and purification techniques and our ADC platform, we not only help our clients accelerate marketing approval by shortening R&D cycles and reducing R&D costs, but also support their marketing needs by consistently delivering large volume and high quality batches at competitive prices. MabPlex’s quality systems strictly follow GMP requirements by USA/EU/Chinese regulatory authorities. Our antibody CMO services can meet our customers’ need for IND filing and PhaseⅠ-Ⅲ clinical studies in USA,EU,AND China.